4:01 pm Qiagen announced it has acquired an exclusive worldwide license to the biomarker calreticulin, whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms, a group of blood disorders – HedgeChatter

4:01 pm Qiagen announced it has acquired an exclusive worldwide license to the biomarker calreticulin, whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms, a group of blood disorders

11 Apr

4:01 pm Qiagen announced it has acquired an exclusive worldwide license to the biomarker calreticulin, whose recently discovered mutations are found in an estimated 15% of cases of myeloproliferative neoplasms, a group of blood disorders

Bystocknews QGEN, stock Comments Off

View todays social media effects on QGEN

View the latest stocks trending across Twitter. Click to view dashboard

See who Qiagen is hiring next, click here to view

Author